Global Biopharmaceutical Third Party Logistics (3PL) Industry: Key Statistics and Insights in 2024-2032

Biopharmaceutical Third Party Logistics (3PL) Industry

Summary:

• The global biopharmaceutical third party logistics (3PL) market size reached USD 123.0 Billion in 2023.
• The market is expected to reach USD 195.4 Billion by 2032, exhibiting a growth rate (CAGR) of 5.2% during 2024-2032.
• North America leads the market, accounting for the largest biopharmaceutical third party logistics (3PL) market share.
• Non-cold chain accounts for the majority of the market share in the supply chain segment due to the high volume of biopharmaceutical products that do not require temperature-controlled environments. 
• Warehousing and storage hold the largest share in the biopharmaceutical third party logistics (3PL) industry.
• The rise in the need for efficient and reliable third-party logistics (3PL) services in the biopharmaceutical industry is a primary driver of the biopharmaceutical third-party logistics (3PL) market.
• The growing need for temperature-sensitive products is reshaping the biopharmaceutical third party logistics (3PL) market.

Request for a sample copy of this report: https://www.imarcgroup.com/biopharmaceutical-third-party-logistics-market/requestsample

Industry Trends and Drivers:

• Increased Globalization of Pharmaceutical Supply Chains:

The rising need for efficient and reliable third-party logistics (3PL) services in the biopharmaceutical industry is impelling the growth of the market. As biopharma companies expand their reach to international markets, the complexity of transporting sensitive materials across borders increases. This necessitates a highly specialized logistics infrastructure capable of managing cross-border regulations, cold-chain requirements, and real-time tracking. 3PL companies offer comprehensive solutions that include warehousing, distribution, and transportation, ensuring compliance with international regulatory standards. Moreover, the global expansion of biopharma companies, particularly in emerging markets, creates opportunities for 3PL providers to facilitate cost-effective, scalable, and adaptable logistics solutions that align with the growing demand for timely delivery of medicines and biologics across diverse regions.

• Rising Demand for Temperature-Sensitive Products:

Biopharmaceuticals often involve temperature-sensitive materials, such as vaccines, biologics, and cell and gene therapies, which require strict handling and storage conditions to maintain efficacy. The rising demand for such products is significantly driving the need for specialized logistics solutions, as any deviations in temperature can compromise the quality of the product. 3PL providers are equipped with advanced cold-chain management systems, including temperature-controlled warehouses and specialized transportation vehicles, to ensure product integrity. As the biopharma industry is innovating with more complex and sensitive treatments, the demand for precise and compliant logistics services is growing. This shift is making 3PL a critical player in ensuring that life-saving drugs reach patients safely and efficiently without compromising on quality.

• Regulatory Compliance and Stringent Industry Standards:

The biopharmaceutical industry operates under stringent regulatory frameworks imposed by global health authorities. These regulations cover every aspect of drug production, storage, and distribution, making compliance a key concern. Third-party logistics providers offer specialized services that ensure adherence to these complex standards. Moreover, they manage the proper labeling of pharmaceutical products, temperature control throughout the supply chain, and ensure that transportation conditions meet regulatory requirements. In many cases, 3PL providers also offer detailed documentation and audit trails, which are essential for regulatory approval and to avoid costly non-compliance penalties. The increasing complexity of regulations, particularly with the rise of biologics and personalized medicine, is driving the demand for 3PL services that can navigate these requirements while ensuring product safety and efficacy.

We explore the factors propelling the biopharmaceutical third party logistics (3PL) market growth, including technological advancements, consumer behaviors, and regulatory changes.

Biopharmaceutical Third Party Logistics (3PL) Market Report Segmentation:

Breakup By Supply Chain:

• Cold Chain
• Non-Cold Chain

Non-cold chain exhibits a clear dominance in the market due to the high volume of biopharmaceutical products that do not require temperature-controlled environments.

Breakup By Service Type:

• Transportation
  • Air Freight
  • Sea Freight
  • Overland
• Warehousing and Storage
• Others

Warehousing and storage represent the largest segment as they rely on third-party providers to handle the specialized needs of storing large quantities of products, ensuring compliance with safety standards and efficient inventory management.

Breakup By Region:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

North America dominates the market, driven by to its advanced healthcare infrastructure, high research investment in biopharma, and the presence of key industry players driving logistics demand.

Top Biopharmaceutical Third Party Logistics (3PL) Market Leaders:

The biopharmaceutical third party logistics (3PL) market research report outlines a detailed analysis of the competitive landscape, offering in-depth profiles of major companies. Some of the key players in the market are:

• Agility Logistics
• AmerisourceBergen Corporation
• DB Schenker (Deutsche Bahn)
• DHL International GmbH (Deutsche Post)
• FedEx Corporation
• Kerry Logistics Network Limited
• Kuehne + Nagel International AG
• McKesson Corporation
• SF Express Co. Ltd.
• United Parcel Service of America Inc.

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145 | United Kingdom: +44-753-713-2163